Home > Cardiology > ESC 2020 > Hot Line Presentations > DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes

DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes

Presented By
Prof. Hiddo Heerspink, University of Groningen, the Netherlands
ESC 2020
DAPA-CKD trial
The DAPA-CKD trial found that the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin reduced worsening kidney function or death from renal or cardiovascular disease by 39% [1]. DAPA-CKD assessed the effects of dapagliflozin on chronic kidney disease (CKD) in patients with and without type 2 diabetes mellitus (T2DM). The reductions of this primary endpoint were 36% and even 50% in patients with and without diabetes, respectively. Previously, the CREDENCE study showed that the SGLT2 inhibitor canagliflozin was associated with a 30% risk reduction in renal decline and cardiovascular and renal death among patients with T2DM [2]. In the DAPA-CKD trial, a third of participants did not have diabetes. This raises the prospect of using dapagliflozin to prevent kidney failure in a new group of patients. Prof. Hiddo Heerspink (University of Groningen, the Netherlands) presented the resu...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on